These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 16166997)

  • 21. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
    Newell DR
    Br J Cancer; 2001 May; 84(10):1289-90. PubMed ID: 11355935
    [No Abstract]   [Full Text] [Related]  

  • 22. BMS-247550 Bristol-Myers Squibb/GBF.
    Lin N; Brakora K; Seiden M
    Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
    DeWys WD; Greenwald P
    Semin Oncol; 1983 Sep; 10(3):360-4. PubMed ID: 6665563
    [No Abstract]   [Full Text] [Related]  

  • 25. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
    Chabner BA; Wittes R; Hoth D; Hubbard S
    Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 28. Developmental therapeutics program at the NCI: molecular target and drug discovery process.
    Monga M; Sausville EA
    Leukemia; 2002 Apr; 16(4):520-6. PubMed ID: 11960328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New NIH center broadens scope of translational research.
    Jenks S
    J Natl Cancer Inst; 2012 May; 104(10):728-31. PubMed ID: 22544941
    [No Abstract]   [Full Text] [Related]  

  • 30. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

  • 31. Screening at the National Cancer Institute.
    Goldin A; Venditti JM; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
    [No Abstract]   [Full Text] [Related]  

  • 32. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
    Croasdell G; Gale S
    IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
    [No Abstract]   [Full Text] [Related]  

  • 33. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CC-5013 (Celgene).
    Mitsiades CS; Mitsiades N
    Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TG-4010 Transgene.
    Cohen S; Kaufman HL
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 37. Investigational new drugs in cancer chemotherapy.
    Peterson BA; Briscoe K
    Minn Med; 1979 Jul; 62(7):536-8. PubMed ID: 386073
    [No Abstract]   [Full Text] [Related]  

  • 38. [Present strategy for new drug development in the USA].
    Shimada Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FR-901228 Fujisawa/National Cancer Institute.
    Vigushin DM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1396-402. PubMed ID: 12498018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New sources and new antitumor drugs in development.
    Weiss RB
    Semin Oncol; 1997 Apr; 24(2):153-5. PubMed ID: 9129685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.